FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Nov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant …
Oct 28, 2024 · Merck and Moderna have initiated Phase 3 randomized clinical trials evaluating mRNA-4157 (V940) in combination with KEYTRUDA as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma (INTerpath-001, NCT05933577 ) and non-small cell lung cancer (INTerpath-002, NCT06077760 ).
Merck Presents Three-Year Survival Data for KEYTRUDA® …
Oct 16, 2020 · Cohort G of the Phase 1/2, multi-cohort, multi-center, open-label trial evaluated KEYTRUDA in combination with chemotherapy (n=60) versus chemotherapy alone (n=63) as first-line treatment in patients with advanced nonsquamous NSCLC. Patients in Cohort G had no EGFR or ALK genomic tumor aberrations.
Moderna And Merck Announce mRNA-4157 (V940) In …
Dec 14, 2023 · mRNA-4157 (V940) is a novel investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) consisting of a synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor.
Merck's Keytruda helps early-stage TNBC patients live longer
Sep 15, 2024 · Merck & Co. Keytruda PD-1/L1 ESMO 2024. In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now,...
FDA Grants Priority Review to Merck's Application for KEYTRUDA ...
Feb 20, 2024 · NRG-GY018, also known as Merck’s KEYNOTE-868, is a randomized, blinded, placebo-controlled Phase 3 trial (ClinicalTrials.gov, NCT03914612) evaluating KEYTRUDA in combination with standard of care chemotherapy (carboplatin and paclitaxel) versus placebo plus standard of care chemotherapy for the treatment of measurable stage III, IVA, IVB or recu...
Health Canada Approves KEYTRUDA - Merck Canada
Apr 19, 2024 · as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy. Approval is based on the Phase 3 KEYNOTE-859 Trial.
Health Canada Approves KEYTRUDA - Merck Canada
Health Canada Approves KEYTRUDA. ®. for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin. Approval is based on the Phase 3 …
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib ... - Merck …
Dec 21, 2023 · KIRKLAND, QC, and MISSISSAUGA, ON, December 21, 2023 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA ®, Merck’s anti-PD-1 therapy, plus LENVIMA ®, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, is now reimbursed with clinical criteria and ...
KEYTRUDA® (pembrolizumab) - Official Site
KEYTRUDA is a prescription medicine used to treat a kind of uterine cancer called advanced endometrial carcinoma. KEYTRUDA may be used with the chemotherapy medicines carboplatin and paclitaxel, and then KEYTRUDA may be used alone, in adults:
- Some results have been removed